| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 2, 2026 | SK bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine-Development Decisions | SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework.
SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical deve... |
| Jun 9, 2026 | SK bioscience Joins Forces with Global Institutions to Advance Rotavirus Vaccine Development | SK bioscience licenses vaccine technology from the U.S. Centers for Disease Control and Prevention
SK bioscience is jointly investing with the RIGHT Foundation to drive process development that enhances both efficacy and productivity
"... |
| Jun 2, 2026 | SK bioscience Secures First UNICEF Procurement Contract Improving Vaccine Access | First UNICEF procurement contract strengthens SK bioscience's presence in global public procurement markets
Dual-hemisphere supply programs enhance manufacturing efficiency and operational capabilities
Public procurement programs drive both... |
| May 29, 2026 | SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund | SK bioscience's board approval follows the Financial Services Commission's May 28 announcement selecting the company as a beneficiary of the KRW 300 billion (approximately USD 230 million) Korea Growth Fund financing program
SK bioscience b... |
| May 26, 2026 | SK bioscience Signs Vaccine Technology Transfer Agreement with Colombia's VECOL to Advance Local Vaccine Manufacturing in Latin America | SK bioscience collaborates with Colombia's government-led US$260 million vaccine localization initiative through technology transfer and local manufacturing cooperation with state-owned pharmaceutical company VECOL
This alliance enables SK ... |
| Mar 18, 2026 | SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support | Largest-ever grant from RIGHT Foundation to accelerate Phase 1b clinical trial of RSV preventive antibody
Technology licensed from Gates MRI; early studies confirm suppression of RSV infection
Targeting global markets while addressing unmet... |
| Feb 26, 2026 | SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union | SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP) vaccines in Europe to improve vaccine performance and access.
Parallel development of high-immunogenicity HD-MAP vaccines for seasonal and... |
| Jan 29, 2026 | SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family | Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family
Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology
SK bioscience will continue to ... |
| Jan 25, 2026 | Global Health Frontlines: Innovation Accelerates Vaccine and Diagnostic Access | Global health initiatives are rapidly advancing critical medical innovations. A major collaboration, backed by CEPI, focuses on enhancing the Zaire ebolavirus vaccine. SK bioscience, MSD, and Hilleman Laboratories are improving manufacturin... |
| Jan 22, 2026 | SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding | CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccine
Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability
Partnership aims to expand afforda... |
| Nov 5, 2025 | IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025 | Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics
Strengthening global CDMO strategy through strategic synergy with SK bioscience
Sustainable growth expected, backed by European comm... |
| Oct 15, 2025 | SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia | Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses
Phase 1/2 study to enroll ~500 healthy adults, with topline results expected by 2028
We aim to build a universal Sarbecovirus vaccine platform to proactively... |
| Sep 2, 2025 | SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift | Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027
Rising demand for 2-dose regimen as international standards amid projected global market growth to USD 6.3 billion by 3034
SKBS continu... |
| Aug 21, 2025 | SK bioscience Discusses Further Collaboration with the Gates Foundation to Advance Global Health | Company holds a dedicated meeting with Gates Foundation executives during Bill Gates' visit to Korea.
Both reviews expanded cooperation, including next-generation preventive medicines.
SEONGNAM, South Korea, Aug. 21, 2025 /PRNewswire/ -- SK... |
| Jul 17, 2025 | SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate | Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant
Interim results from the Phase 1/2 trial expected by 2027, aimed at entering the high-immunogenicity vaccine market
"... |
| May 21, 2025 | SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine | No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia
Company plans to export PCV13 vaccine components
"We aim for the global PCV market with our 21-valent... |
| May 8, 2025 | South Korea's Vaccine Vanguard: SK bioscience Takes Aim at Avian Influenza | In a world still reeling from the COVID-19 pandemic, the specter of avian influenza looms large. South Korea's SK bioscience is stepping up to the plate, armed with innovation and a sense of urgency. The company has joined forces with the K... |
| May 6, 2025 | SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats | Company aims to develop a bird flu vaccine with rapid mass production and variant responsiveness.
SK bioscience and KDCA join forces to build a national pandemic preparedness and response system for potential next-pandemic avian influenza.
... |
| Feb 25, 2025 | SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate | SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026
Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding sup... |
| Dec 12, 2024 | SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate | SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials in Australia in February 2025, with interim results expected by 2026.
Joint R&D project between SK and CEPI includes up to USD 40 million in initial fundi... |
| Oct 23, 2024 | SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia | This approval paves the way for exports to the world's fourth most populous country.
SK bioscience aims to continue to grow as a global vaccine brand beyond Korea by leveraging the advantages of cell-cultured vaccines.
SEONGNAM, South Korea... |
| Oct 8, 2024 | Korea's SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions | SK bioscience invested USD 3 million in FinaBio, a U.S. company specializing in next-generation conjugate vaccine technology.
With the agreement, SK bioscience expects to improve the immunogenicity and productivity of conjugate vaccines, in... |
| Oct 4, 2024 | SK bioscience Completes Acquisition of IDT Biologika | SK biosciences, a Seongnam, South Korea-based global vaccine and biotech company, acquired a controlling stake in a IDT Biologika, a German vaccine contract development manufacturing organizations (CDMO).
The amount of the deal was not disc... |
| Oct 2, 2024 | South Korea's SK bioscience Completes Acquisition of Germany's CDMO IDT Biologika | SK bioscience completed the acquisition of German CDMO company IDT Biologika with over a century of history that enables immediate expansion in revenue and infrastructure.
The company aims to double sales of IDT Biologika by 2028 through ne... |
| Mar 21, 2024 | SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market | Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market.
Company has obtained marketing authorizations in 12 countries, with additional approvals underway in 10 countr... |
| Aug 23, 2023 | VAXXAS AWARDED US$3.67 MILLION (AU$5.4 MILLION) FROM GLOBAL CHARITABLE FOUNDATION, WELLCOME, FOR HUMAN CLINICAL STUDY OF TYPHOID VACCINATION USING NEEDLE-FREE VACCINE PATCH | Cambridge, Mass., USA, and Brisbane, Queensland, Australia – August 23, 2023 – Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that the global charitable foundation, Wellcome, has... |
| May 23, 2023 | SK bioscience Presents Solution for Equitable Access of Vaccine at Regionalized Vaccine Manufacturing Collaborative of World Economic Forum | Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine M... |
| Feb 8, 2023 | SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center | The additional investment for the 'R&PD Center' was confirmed by the board of directors committee with a total of 261 million USD
SK bioscience plans to establish a vaccine-biopharmaceutical hub, organizing a global cooperative model ag... |
| Jan 27, 2023 | SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs | SK bioscience shared a development history of the South Korea's first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in the Kingdom of Saudi Arabia(KSA)
SK bioscience also explained a new global partner... |
| Jan 20, 2023 | SK bioscience Appoints New Executives to Accelerate New Growth Strategies | Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
With recruitment of global talent and capabilities accumulated during the COVID-19 pandemic, SK bioscience will continue to achieve sustainable growth
SEOU... |
| Jan 10, 2023 | China is still racing to develop its own mRNA jabs. But they won't use foreign vaccines to fight COVID because of 'national pride,' says South Korea's top vaccine maker. | Chinese officials say domestically developed COVID-19 vaccines are effective. CFOTO/Future Publishing/Getty Images
China's grappling with a surge in COVID-19 cases since it abandoned its zero-COVID policy in December.
It hasn't yet approved... |
| Novavax posts surprise quarterly profit as company prepares to launch new Covid vaccine | Shares of Novavax jumped after the Covid vaccine maker reported a surprise second-quarter profit.
The results come as Novavax works to strengthen its financial position, especially after it raised doubts earlier this year about its ability ... |
